Peptides have gone from biochemistry footnote to mainstream wellness obsession. Scroll through any longevity podcast, fitness forum, or functional medicine clinic’s menu and you’ll find BPC-157, TB-500, and MOTS-c discussed with the confidence usually reserved for well-established therapies. The promise is compelling: targeted molecular signaling that accelerates tissue repair, reduces inflammation, and supports cellular health at a level supplements can’t reach.

But there’s a significant gap between “promising in animal studies” and “proven safe and effective in humans.” Understanding that gap is essential for anyone considering peptides for recovery and longevity — and knowing your metabolic baseline before starting any protocol is even more important.

BPC-157: The Tissue Repair Peptide

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. It is the most widely discussed recovery peptide in the wellness space, marketed for tendon healing, gut repair, and inflammation reduction.

The preclinical data is genuinely interesting. Over 35 animal studies have demonstrated that BPC-157 promotes angiogenesis (the growth of new blood vessels), stimulates fibroblast activity and collagen synthesis, and modulates nitric oxide and serotonin pathways involved in inflammation. In rat models, it has shown benefit for severed Achilles tendons, muscle crush injuries, and even traumatic brain injury.

However, the human evidence is extremely limited. A 2025 systematic review published in HSS Journal identified only one clinical study — a retrospective case series of twelve patients receiving intra-articular BPC-157 injections for knee pain. Most patients reported subjective improvement, but the study had no controls, no randomization, and significant methodological limitations. A separate 2025 pilot study assessed intravenous BPC-157 in just two healthy adults and confirmed short-term tolerability — but generated no efficacy data.

BPC-157 is not FDA-approved for any indication. The FDA has classified it as a Category 2 bulk drug substance, meaning compounding pharmacies cannot legally produce it. It is also on the World Anti-Doping Agency’s Prohibited List. Despite this, it remains widely available online and through wellness clinics.

TB-500 (Thymosin Beta-4): The Cell Migration Peptide

TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring 43-amino-acid peptide found throughout the human body — with particularly high concentrations in platelets and wound fluid. Its primary biological function is actin sequestration, which governs cell motility and migration. In tissue repair, this means TB-500 may help recruit the body’s repair cells to injury sites more effectively.

Compared to BPC-157, thymosin beta-4 has a stronger clinical track record. Phase I trials confirmed safety with no dose-limiting toxicities. Phase II data has shown measurable benefit across multiple conditions: a 35% reduction in ocular discomfort in dry eye syndrome, reduced cardiac scar volume after heart attack, and accelerated healing in chronic wound trials where ulcers healed nearly a month faster than controls.

That said, TB-500 specifically (the synthetic fragment marketed in wellness contexts) is not the same compound used in these clinical trials. It is not FDA-approved, and its use outside of clinical research lacks the quality control and dosing precision of regulated pharmaceutical products.

MOTS-c: The Mitochondrial Peptide

MOTS-c is arguably the most metabolically relevant peptide in this conversation — and the one most directly connected to what PNOĒ measures.

MOTS-c is a mitochondrial-derived peptide encoded by mitochondrial DNA. It regulates insulin sensitivity, glucose homeostasis, and fat metabolism through AMPK activation — the same energy-sensing pathway activated by exercise. Research published in Cell Metabolism demonstrated that MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance in animal models. Additional studies in the American Journal of Physiology confirmed that circulating MOTS-c levels decline with age and that conditions like obesity, diabetes, and metabolic dysfunction are associated with lower MOTS-c levels.

What makes MOTS-c particularly interesting is that it mirrors the benefits of exercise at a cellular level. Researchers have speculated that it may function as an “exercise mitokine” — a signaling molecule released during physical activity that mediates some of the metabolic benefits of training. Resistance training has been shown to increase intramuscular humanin expression (a related mitochondrial-derived peptide), suggesting that exercise itself may be the most effective “peptide protocol” available.

MOTS-c is still in the research phase and is not commercially available as a therapy. But it highlights a key principle: mitochondrial function is central to peptide response, and measuring that function — through breath testing — provides the data needed to understand whether your cells are ready to benefit.

The Metabolic Blind Spot in Peptide Therapy

The pattern in the peptide space mirrors what we see with GLP-1s and supplements: people pursue interventions without first understanding their metabolic baseline.

Peptides targeting tissue repair depend on adequate blood flow and vascular health. Peptides targeting mitochondrial function depend on cells that are already producing energy reasonably well. Peptides marketed for recovery depend on a body that has the cardiovascular and muscular capacity to respond to the signals being sent.

If VO2 Max is low, fat oxidation is inefficient, resting metabolic rate is suppressed, or insulin resistance is present, the body’s ability to respond to any peptide is compromised.

A PNOĒ breath test measures all of these markers in a single session:

• VO2 Max — cardiovascular and mitochondrial ceiling
• Fat oxidation rate — how well cells access fat for energy
• RMR — baseline metabolic output, reflecting mitochondrial health
• Metabolic flexibility — the ability to switch fuel sources, a proxy for insulin sensitivity

This is the metabolic foundation that every intervention — whether it’s BPC-157, MOTS-c, or a creatine supplement — ultimately depends on.

The Bottom Line: Promising, But Not Proven

Peptides for recovery and longevity are generating exciting preclinical data. BPC-157’s tissue repair mechanisms are well-documented in animal models. Thymosin beta-4 has real Phase II human data. MOTS-c may represent a breakthrough in understanding how mitochondria communicate with the rest of the body.

But the confidence gap between marketing and evidence remains wide. Most popular peptides lack rigorous, large-scale human trials. Quality control in the compounding and online market is inconsistent. And none of these peptides have FDA approval for the indications they’re most commonly marketed for.

The smartest approach isn’t to avoid peptides entirely — it’s to demand data. Start with your metabolic baseline. Understand where your body stands. And then, with clinical guidance, decide whether a peptide protocol adds meaningful value on top of a foundation that’s already been measured and optimized.